论文部分内容阅读
目的:探讨薄层液基细胞检测技术(TCT)和高危型人乳头瘤病毒(HPV-DNA)联合检测在早期宫颈癌筛查中的应用。方法:选取2014年6月-2016年6月在我院进行早期宫颈癌筛查的患者1500例,以病理诊断结果为金标准,评价TCT联合HPV-DNA检测在早期宫颈癌筛查中的准确性。结果:HPV-DNA共检出阳性患者887例(59.13%),且随着病情逐渐加重,HPV-DNA阳性率越高。灵敏度:HPV-DNA检查>TCT联合HPV-DNA检查>TCT检查。阴性预测值:TCT联合HPV-DNA检查>HPV-DNA检查>TCT检查。TCT联合HPV-DNA检查特异度、准确度和阳性预测值均显著高于TCT和HPV-DNA单一检查(P<0.05)。结论:TCT联合HPV-DNA检测可提高早期宫颈癌筛查的特异度和准确度,具有重要的临床应用价值。
Objective: To investigate the application of the combination of thin-layer liquid-based cell detection (TCT) and high-risk human papillomavirus (HPV-DNA) in the screening of early cervical cancer. Methods: One hundred and fifty-five patients with early cervical cancer screening in our hospital from June 2014 to June 2016 were selected. The accuracy of TCT combined with HPV-DNA screening in early screening of cervical cancer was evaluated with the pathological diagnosis as the gold standard Sex. Results: A total of 887 positive cases (59.13%) were detected by HPV-DNA. The positive rate of HPV-DNA increased with the progression of the disease. Sensitivity: HPV-DNA test> TCT combined with HPV-DNA test> TCT test. Negative predictive value: TCT in combination with HPV-DNA test> HPV-DNA test> TCT test. TCT combined with HPV-DNA test specificity, accuracy and positive predictive value were significantly higher than TCT and HPV-DNA single test (P <0.05). Conclusion: TCT combined with HPV-DNA test can improve the specificity and accuracy of early cervical cancer screening, which has important clinical value.